Literature DB >> 2161221

Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells.

T J Resink1, A W Hahn, T Scott-Burden, J Powell, E Weber, F R Bühler.   

Abstract

This study demonstrates the induction of endothelin (ET) mRNA expression and synthesis of functional ET peptide in cultured human vascular smooth muscle cells (hVSMC). Compounds eliciting such responses in hVSMC include the vasoconstrictor hormones angiotensin II and arginine-vasopressin and the growth factors transforming growth factor beta, platelet derived growth factor AA and epidermal growth factor. Induction of ET mRNA expression in hVSMC exhibited transient kinetics (peak at 3-5 hrs. and return to basal within 7 hrs.) which differed from the more sustained ET transcript induction observed for porcine endothelial cells. ET peptide (determined by both radioimmuno- and radioreceptor assays) produced by stimulated hVSMC attained levels (approximately 120-160 pg/10(6) cells/4 hrs.; concentration approximately 3 x 10(-11) M) within the biologically effective concentration range of ET. Stimulated secretion of ET from hVSMC was abolished in the presence of the protein synthesis inhibitor cycloheximide. Sep-pak C18 extracts of medium from stimulated hVSMC elicited a concentration-dependent phosphoinositide catabolic response in myo-[2-3H]-inositol-prelabelled hVSMC. Our findings invoke a role for ET which extends beyond the paracrine regulation by peptide synthesized and secreted by endothelial cells. We propose that VSMC-synthesized ET may function in an autocrine manner to regulate both tone and structural modelling of vasculature.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161221     DOI: 10.1016/0006-291x(90)91171-n

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Big endothelin-1 but not endothelin-1 is present in the smooth muscle stroma of the prostate gland of the rat.

Authors:  S Ventura; A Salamoussa
Journal:  J Anat       Date:  2002-02       Impact factor: 2.610

Review 2.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

3.  Endothelin-1 mRNA expression in the rat kidney.

Authors:  D J Nunez; E A Taylor; V M Oh; J P Schofield; M J Brown
Journal:  Biochem J       Date:  1991-05-01       Impact factor: 3.857

Review 4.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 5.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 6.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

7.  Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.

Authors:  Arnaud Mansart; Lewis J Ruff; Mark P Ariaans; Jonathan J Ross; Charles S Reilly; Nicola J Brown; Susan Kaufman; Zoë L S Brookes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-16       Impact factor: 3.000

8.  Heart ischaemia-reperfusion induces local up-regulation of vasoconstrictor endothelin ETB receptors in rat coronary arteries downstream of occlusion.

Authors:  G F Skovsted; L S Kruse; R Larsen; A F Pedersen; S Trautner; M Sheykhzade; L Edvinsson
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Secretion of immunoreactive endothelin-1 by capillary and microvascular endothelium of human brain.

Authors:  F Bacic; S Uematsu; R M McCarron; M Spatz
Journal:  Neurochem Res       Date:  1992-07       Impact factor: 3.996

Review 10.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.